Gene · 1806
Papers4,420
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 4,420
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Antiosteoporosis and Bone Protective Effect of Phyllanthin Against Glucocorticoid-induced Osteoporosis in Rats via Alteration of HO-1/Nrf2 and RANK/RANKL/OPG Pathway. | Dokl Biochem Biophys | 2025 | 39849266 | PubTator, text mining | PubMed |
| A novel piperine derivative HJJ_3_5 inhibits colorectal cancer progression by modulating EMT signaling pathways. | Biochem Biophys Res Commun | 2025 | 39842333 | PubTator, text mining | PubMed |
| Dihydropyrimidine enzyme activity and its effect on chemotherapy toxicity: importance of genetic testing. | Cancer Chemother Pharmacol | 2025 | 39825952 | PubTator, text mining | PubMed |
| Dihydropyrimidine dehydrogenase polymorphisms in patients with gastrointestinal malignancies and their impact on fluoropyrimidine tolerability: Experience from a single Italian institution. | World J Gastrointest Oncol | 2025 | 39817118 | PubTator, text mining | PubMed |
| Activation of sphingosine-1-phosphate receptor 2 (S1PR2) upregulates dihydropyrimidine dehydrogenase (DPD) expression in colon cancer cells. | J Adv Res | 2025 | 39814224 | PubTator, text mining | PubMed |
| DPYD genotype should be extended to rare variants: report on two cases of phenotype / genotype discrepancy. | Cancer Chemother Pharmacol | 2025 | 39745516 | PubTator, text mining | PubMed |
| Pharmacogenomics: DPYD and Prevention of Toxicity. | Clin Oncol (R Coll Radiol) | 2025 | 39721301 | PubTator, text mining | PubMed |
| Intratumoural expression of dihydropyrimidine dehydrogenase is an independent prognostic factor in resected pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine. | Oncol Lett | 2025 | 39703529 | PubTator, text mining | PubMed |
| Clinical Pharmacogenetic Testing and Application: 2024 Updated Guidelines by the Korean Society for Laboratory Medicine. | Ann Lab Med | 2025 | 39681357 | PubTator, text mining | PubMed |
| Give Patients the Choice to Test for DPD Deficiency Before Fluoropyrimidine Chemotherapy. | JCO Oncol Pract | 2025 | 39626133 | PubTator, text mining | PubMed |
| The impact of diet-induced obesity on 5 fluorouracil-induced tumor and liver immune cell cytotoxicity. | Am J Physiol Cell Physiol | 2025 | 39570672 | PubTator, text mining | PubMed |
| Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice. | J Clin Oncol | 2025 | 39481076 | PubTator, text mining | PubMed |
| Ischemic cardiopathy induced by capecitabine in gastric cancer: The role of dihydropyrimidine dehydrogenase metabolites. | Therapie | 2025 | 39438243 | PubTator, text mining | PubMed |
| Management of patients with reduced dihydropyrimidine dehydrogenase activity receiving combined 5-fluoruracil-/capecitabine-based chemoradiotherapy. | Strahlenther Onkol | 2025 | 39230592 | PubTator, text mining | PubMed |
| Implementation of a pharmacist-guided pharmacogenomics dosing service at a rural NCI-designated comprehensive cancer center. | J Oncol Pharm Pract | 2025 | 39228222 | PubTator, text mining | PubMed |
| Administration mode matters for 5-fluorouracil therapy: Physiologically based pharmacokinetic evidence for avoidance of myelotoxicity by continuous infusion but not intravenous bolus. | Br J Clin Pharmacol | 2025 | 38627941 | PubTator, text mining | PubMed |
| Implementation of pre-emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand? | Br J Clin Pharmacol | 2025 | 37926674 | PubTator, text mining | PubMed |
| Single-cell atlas of transcriptomic vulnerability across multiple neurodegenerative and neuropsychiatric diseases. | medRxiv | 2024 | 41602098 | PubTator, text mining | PubMed |
| The Frequency of DPYD c.557A>G in the Dominican Population and Its Association with African Ancestry. | Pharmaceutics | 2024 | 39861660 | PubTator, text mining | PubMed |
| Methylenetetrahydrofolate Reductase (MTHFR) Variants and Severe Capecitabine Toxicity: A Case Report and Review of Literature. | Cureus | 2024 | 39816293 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1806/papers?page=11